Furthermore, due to the high orexigenic and adipogenic action of MCH, the therapeutic use of MCH agonist should be considered in the treatment of other diseases characterized by the chronic loss of lean or fat mass, such as sarcopenia or cachexia. This evidence concerns the gene PMCH and sarcopenia.